donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
AZN AstraZeneca
65.120
-0.910-1.38%
Post Mkt Price
65.200
+0.08+0.12%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
31.03% 10.77B 55.6% 11.39B 40.58% 37.42B 62.09% 12.01B
Operating revenue
31.03% 10.77B 55.6% 11.39B 40.58% 37.42B 62.09% 12.01B
Cost of revenue
36.83% 3B 88.36% 3.51B 134.7% 12.44B 203.28% 4.63B
Gross profit
28.93% 7.77B 44.41% 7.88B 17.18% 24.98B 25.51% 7.39B
Operating expense
47.57% 7.23B 96.6% 7B 42.5% 25.11B 74.58% 7.68B
Selling and administrative expenses
50.27% 4.81B 63.97% 4.97B 31.01% 15.59B 57.91% 5.24B
-Selling and marketing expense
50.27% 4.81B 63.97% 4.97B 31.01% 15.59B 57.91% 5.24B
Research and development costs
39.2% 2.55B 24.52% 2.13B 56.7% 9.74B 50.32% 2.58B
-Depreciation and amortization
-- -- -- -- -50% 1M -- --
Other operating expenses
-- -- 91.78% -97M 352.94% 308M 77.03% -147M
Operating profit
-52.17% 539M -53.67% 878M -103.63% -134M -119.64% -292M
Net non-operating interest income expense
8.15% -293M -12.72% -319M -3.7% -1.23B -6.69% -335M
Non-operating interest income
157.14% 18M -15% 17M -48.19% 43M -85.71% 1M
Non-operating interest expense
-4.6% 311M 10.89% 336M 0.31% 1.28B 4.67% 336M
Other net income (expense)
Special income (charges)
-- -- -- -- -18.94% 1.19B -- --
-Less:Restructuring and merger&acquisition
-- -- -- -- 124.23% 47M -- --
-Less:Other special charges
-- -- -- -- 3.81% -1.24B -- --
Income before tax
-67.67% 247M -65.61% 553M -106.77% -265M -154.5% -636M
Income tax
-152.8% -113M 258.7% 165M -149.22% -380M -279.01% -290M
Net income
-34.55% 360M -75.16% 388M -96.34% 115M -134.43% -346M
Net income continuous Operations
-34.55% 360M -75.16% 388M -96.34% 115M -134.43% -346M
Minority interest income
0 100% 2M 105.77% 3M 114.29% 1M
Net income attributable to the parent company
-34.55% 360M -75.27% 386M -96.5% 112M -134.29% -347M
Preferred stock dividends
Other preferred stock dividends
0 0 0 0
Net income attributable to common stockholders
-34.55% 360M -75.27% 386M -96.5% 112M -134.29% -347M
Basic earnings per share
-45.24% 0.115 -78.99% 0.125 -96.72% 0.04 -128.21% -0.11
Diluted earnings per share
-45.24% 0.115 -78.81% 0.125 -96.72% 0.04 -128.21% -0.11
Dividend per share
0 3.68% 0.985 0% 1.4 0
Currency Unit
USDUSDUSDUSD
Accounting Standards
NonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAP

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
CEO: Soriot M.B.A., Pascal
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...